Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies. At Protagonist, we strive to improve patients’ lives through the power of drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate. Protagonist is a clinical-stage biopharmaceutical company committed to developing novel peptide-based drugs to address significant unmet medical needs and making them available broadly to patients as quickly as possible by conducting the clinical trials necessary to gain approval by regulatory authorities. We have five novel peptidic assets currently in different stages of clinical studies. Rusfertide (PTG-300) is a hepcidin mimetic currently being studied as a treatment for polycythemia vera (PV) and hereditary hemochromatosis (HH). PN-943 is an α4β7 integrin-specific antagonist being studied in patients with moderate-to-severely active ulcerative colitis (UC). In October 2020, we announced the selection of two second-generation IL-R antagonists for advancement into clinical development, PN-235 (also referenced as JNJ-77242113) and PN-232 (also referenced as JNJ-75105186). (Source: https://www.protagonist-inc.com/home-page/default.aspx)